Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 21, 2017
What is the patent landscape for Promacta, and what generic Promacta alternatives are available?
Promacta is a drug marketed by Novartis Pharms Corp and is included in two NDAs. There are fourteen patents protecting this drug and two Paragraph IV challenges.| Patents: | 14 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: see list | 2 |
| Bulk Api Vendors: see list | 47 |
| Clinical Trials: see list | 25 |
| Patent Applications: see list | 82 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | PROMACTA at DailyMed |
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| eltrombopag olamine | Tablets | 50 mg and 75 mg | Promacta | 1/7/2014 |
| eltrombopag olamine | Tablets | 12.5 mg and 25 mg | Promacta | 2/4/2014 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,211,200 | Metal complexes | ► Subscribe | |||||||||||||||||||||||||||
| 7,648,971 | Thrombopoietin mimetics | ► Subscribe | |||||||||||||||||||||||||||
| 8,088,813 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | ► Subscribe | |||||||||||||||||||||||||||
| 7,439,342 | Thrombopoietin mimetics | ► Subscribe | |||||||||||||||||||||||||||
| 7,335,649 | Thrombopoietin mimetics | ► Subscribe | |||||||||||||||||||||||||||
| 6,413,952 | Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal | ► Subscribe | |||||||||||||||||||||||||||
| 7,674,887 | Thrombopoietin mimetics | ► Subscribe | |||||||||||||||||||||||||||
| 8,846,024 | 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-y- lidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norway | 20025566 | ► Subscribe | |||||||||||||||||||||||||||
| Hong Kong | 1055561 | ► Subscribe | |||||||||||||||||||||||||||
| Hong Kong | 1136968 | ► Subscribe | |||||||||||||||||||||||||||
| Malaysia | 142390 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 100847172 | ► Subscribe | |||||||||||||||||||||||||||
| Spain | 2334843 | ► Subscribe | |||||||||||||||||||||||||||
| Costa Rica | 11143 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2411468 | ► Subscribe | |||||||||||||||||||||||||||
| Taiwan | 200407128 | ► Subscribe | |||||||||||||||||||||||||||
| Chile | 2007002242 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C020/2010 | Ireland | ► Subscribe | SPC020/2010: 20110308, EXPIRES: 20250310 | ||||||||||||||||||||||||||
| 2010000037 | Germany | ► Subscribe | PRODUCT NAME: ELTROMBOPAG SOWIE PHARMAZEUTISCH ANNEHMBARE SALZE, HYDRATE UND SOLVATE DAVON; NAT. REGISTRATION NO/DATE: EU/1/10/612/001-006 20100311; FIRST REGISTRATION: EU EU/1/10/612/001-/006 20100311 | ||||||||||||||||||||||||||
| 2010007,C1534390 | Lithuania | ► Subscribe | PRODUCT NAME: ELTROMBOPAGUM OLAMINUM; REGISTRATION NO/DATE: EU/1/10/612/001, 2010-03-11 EU/1/10/612/002, 2010-03-11 EU/1/10/612/003, 2010-03-11 EU/1/10/612/004, 2010-03-11 EU/1/10/612/005, 2010-03-11 EU/1/10/612/006 20100311 | ||||||||||||||||||||||||||
| 0100006 00032 | Estonia | ► Subscribe | PRODUCT NAME: REVOLADE-ELTROMBOPAG; REG NO/DATE: C(2010)1662 11.03.2010 | ||||||||||||||||||||||||||
| 2010007 | Lithuania | ► Subscribe | PRODUCT NAME: ELTROMBOPAGUM OLAMINUM; REGISTRATION NO/DATE: EU/1/10/612/001, 2010 03 11 EU/1/10/612/002, 2010 03 11 EU/1/10/612/003, 2010 03 11 EU/1/10/612/004, 2010 03 11 EU/1/10/612/005, 2010 03 11 EU/1/10/612/006 20100311 | ||||||||||||||||||||||||||
| 2010 00017 | Denmark | ► Subscribe | |||||||||||||||||||||||||||
| C0034 | France | ► Subscribe | PRODUCT NAME: ELTROMBOPAG EVENTUELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE (INCLUANT UN HYDRATE; REGISTRATION NO/DATE: EU/1/10/612/001 20100311 | ||||||||||||||||||||||||||
| 8 | Finland | ► Subscribe | |||||||||||||||||||||||||||
| C/GB10/026 | United Kingdom | ► Subscribe | PRODUCT NAME: ELTROMBOPAG, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE (INCLUDING A HYDRATE); REGISTERED: UK EU1/10/612/001 20100311; UK EU1/10/612/002 20100311; UK EU1/10/612/003 20100311; UK EU1/10/612/004 20100311; UK EU1/10/612/005 20100311; UK EU1/10/612/006 20100311 | ||||||||||||||||||||||||||
| /2010 | Austria | ► Subscribe | PRODUCT NAME: ELTROMBOPAG, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS UND SOLVATS DAVON; REGISTRATION NO/DATE: EU/1/10/612/001-006 20100311 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,720 others who get our Drug Patent Expiration Alerts:
